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Abstract 
We report on Mycobacterium tuberculosis thymidine monophosphate kinase (TMPKmt) inhibitory 
activities of a series of new 3’- and 5’-modified thymidine analogues including α- and β-derivatives. In 
addition, several analogues were synthesized in which the 4-oxygen was replaced by a more lipophilic 
sulfur atom to probe the influence of this modification on TMPKmt inhibitory activity. Several 
compounds showed an inhibitory potency in the low micromolar range, with the 5’-arylthiourea 4-thio-
α-thymidine analogue being the most active one (Ki = 0.17 μM). This compound was capable of 
inhibiting mycobacteria growth at a concentration of 25 μg/mL. 
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1. Introduction 
Worldwide, tuberculosis (TB) remains one of the leading causes of death from infectious diseases. 
About one third of the world’s population is infected with Mycobacterium tuberculosis that causes TB. 
On average 5-10% of these carriers become sick or infectious at some time during their life. Annually, 
more than 9 million new cases are reported and TB claims almost 2 million lives each year.1
TB forms a lethal combination with HIV, each speeding the other's progress. TB is a leading cause of 
HIV-related deaths worldwide. In 2008, there were an estimated 1.4 million new cases of TB among 
persons with HIV infection and TB accounted for 23% of AIDS-related deaths. The global resurgence 
of TB due to HIV infection and the rapid emergence of multidrug-resistant (MDR) and extensively 
drug-resistant (XDR) strains of TB bacilli underscore the importance of developing new 
antimycobacterial drugs against TB.
  
2
Recently, thymidine monophosphate kinase of M. tuberculosis (TMPKmt)
  
3 was put forward as an 
attractive target for new antituberculosis agents.4 TMPK catalyzes the conversion of dTMP to dTDP 
using ATP as phosphate donor and is crucial for maintaining the thymidine triphosphate pools required 
for DNA synthesis and replication of bacteria.  TMPK acts at the junction of the de novo and salvage 
pathways for the synthesis of deoxythymidine triphosphate (dTTP), which is indispensable for growth 
and survival. Therefore, TMPK represents a promising target for developing new TB drugs. 
Experiments with TMPK-deficient mutant of Saccharomyces cerevisiae underscore the criticality of this 
enzyme for DNA replication and cellular growth.5
Although the global folding of TMPKmt is similar to that of other TMPKs, the configuration of its active 
site is unique. Compared to the human isozyme TMPKmt is peculiar in that it is competitively inhibited 
by AZT-MP (Ki = 10 μM), making the latter an attractive starting point for the design of selective 
inhibitors.
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On the basis of the structure of a dinucleoside 1 (Chart 1), discovered by chance to produce significant 
inhibition of TMPKmt (Ki = 37 μM),7 we have prepared a series of 3’-C-arylthiourea derivatives of β-D-
thymidine, which led to the arylthiourea analogue 2 (Ki = 5.0 μM).8
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 Modeling experiments suggested a 
binding mode for these 3’-C-arylthiourea analogues that differs from that of the natural substrate in 
that the sugar ring of the thymidine moiety is tilted over 180° compared to that of dTMP, thereby 
positioning the aromatic 3’-substituent into the phosphoryl donor binding area and the nucleobase 
below the sugar plane (Figure 1). 
 
Figure 1. Suggested inverse sugar binding of 3’-C-arylthiourea-modified β-thymidine 2 and anticipated 
similar relative orientation of the colored moieties in 5’-deoxy-5’-arylthiourea modified α-thymidine 3. 
This unusual binding mode led us to explore if an alternative sugar scaffold could be used to impose a 
similar relative orientation of the thymine and the phenylthiourea moieties for TMPKmt inhibition. It was 
hypothesized that an α-nucleoside in which the 5’-position served as the thiourea anchor might fulfill 
this criterion. From a small library of easily accessible 5’-N-arylthiourea derivatives of α-thymidine, 3 
emerged as one of the most potent TMPKmt inhibitors to date with a Ki of 0.6 µM, a selectivity index 
(versus TMPKh) of 600, and good inhibitory activity on the growing M. bovis (MIC99 20 μg/mL) and M. 
tuberculosis (39% inhibition at 6.25 μg/mL) strains.8 Next to the relative orientation between the aryl 
moiety and the nucleobase, structural exploration of the α-thymidine derivatives revealed the 
importance for aromatic residues at the 5’-position and the positive impact of electronic-withdrawing 
and lipophilic substituents on the aryl moiety for optimal inhibition of TMPKmt. 
In this contribution we report on the TMPKmt inhibitory activities of a series of new thymidine 
analogues. Analogues 4 and 5 represent close analogues of 3’-C-arylthiourea 2, in which the 
methylene group between C-3’ and the (thio)urea group has been omitted.9 Analogues 8-11, derived 
from AZT (6), were selected to investigate if a 1,4-disubstituted 1,2,3-triazole motif can act as a 
bioisostere for the 3’-C-thiourea linker of 2 as previously found to be the case for TK-2 inhibition.10 The 
aminotetrazole isomers 12 and 13 were recently synthesized in the context of TK-2 inhibition11
To assess the inhibitory activity of anomeric variants of 3, its β-anomer 14, as well as two heterocyclic 
analogues 15 and 16 are included in this study. Compounds 18-20 are derived from 5’-azido-5’-deoxy-
α-D-thymidine (17) and synthesized in an effort to improve the activity of compound 3. To further 
 and are 
also characterized by the presence of a heterocyclic linker to connect the aromatic moiety to position 3 
of the 2’-deoxyribofuranose ring.  
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investigate the influence of the relative orientation between the aryl moiety and the nucleobases, 
compound 21, which is the α-analogue of 9, was synthesized and evaluated. 
Based on earlier reports of 4-thiothymidine analogues showing promising antimycobacterial potency 
against M. bovis and M. tuberculosis in vitro and thus capable of entering the bacillus,12
2. Results and discussion 
 several 
analogues were synthesized in which the 4-oxygen of the thymine moiety was replaced by a more 
lipophilic sulfur atom (e.g., 7, 10, 19 and 20) to probe the influence of this modification on TMPKmt 
inhibitory activitity.  
2.1. Chemistry 
With the exception of compounds 7, 10, 14-16, 18-20 and 22, the chemical synthesis of all other final 
compounds has been reported before.9,10,11 For the preparation of 4-thio-AZT (7), 5’-O-acetylated AZT 
2313 was treated with Lawesson’s reagent to generate the corresponding 4-thio pyrimidine 24, 
followed by hydrolysis of the acetate ester (Scheme 1). A CuAAC reaction14,15
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Scheme 1. Reagents and conditions. (a) Lawesson's reagent, toluene, 80 °C, overnight, 20%; (b) 
7N NH3 in MeOH, rt, 6 h, 42%, (c) 1-chloro-4-ethynylbenzene, CuSO4·5H2O, sodium ascorbate, H2O/t-
BuOH 2:1, rt, 24 h, 41%; (d) Lawesson's reagent, toluene, 80 °C, overnight, 49%; (e) 7N NH3 in 
MeOH, rt, 6 h, 66%. 
Coupling of amine 2716
11
 with 4-chloro-3-(trifluoromethyl)phenyl isothiocyanate gave thiourea derivative 
28 which was deprotected using TBAF in THF. A mercury(II)-promoted reaction of 28 with NaN3 and 
Et3N gave access to aminotetrazole 15 after final desilylation (Scheme 2).  
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Scheme 2. Reagents and conditions: (a) 4-chloro-3-(trifluoromethyl)phenyl isothiocyanate, DMF, 0 
°C → rt, 1 h, 76%; (b) 1M TBAF in THF, THF, rt, 1 h, 53-60%; (c) NaN3, HgCl2, Et3N, DMF, 0 °C → rt, 
overnight, 83%.  
The synthesis of the 5’-substituted β-thymidine analogue 16 started from 5’-azido-5’-deoxy-β-
thymidine17 (Scheme 3). “Click chemistry” followed by HPLC purification allowed to isolate enough 
pure material of 16 for testing. 
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Scheme 3. Reagents and conditions: (a) 1-chloro-4-ethynylbenzene, CuSO4·5H2O, sodium 
ascorbate, H2O/t-BuOH 1:2, rt, 7 d, 2%. 
For the synthesis of compounds 18 and 19, 3’,5’-O-diacetyl-α-D-thymidine 3118 was first thionated 
using Lawesson’s reagent followed by deprotection and conversion to the monomesylate ester 34 
(Scheme 4). Upon treatment with NaN3, 34 was converted into azide 35, which was reduced to afford 
the 5’-amino-5’-deoxy-4-thio-α-D-thymidine 36. Final treatment of this amine with the appropriate 
isothiocyanate analogues afforded derivatives 18 and 19.  
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Scheme 4. Reagents and conditions. (a) Lawesson's reagent, anhydrous 1,4-dioxane, reflux, 4 h; 
(b) 7N NH3 in MeOH, rt, 4 h, 37% over 2 steps; (c) MsCl, pyridine, -78 °C → 0 °C, 1 h, 70%; (d) NaN3, 
DMF, 60 °C, overnight, 89%; (e) PPh3, THF, H2O, rt, 1 d, 89%; (f) appropriate isothiocyanate, DMF, 0 
°C → rt, 3 h, 42-69%. 
Starting from 5’-azido-5’-deoxy-α-D-thymidine 17,8 compound 20 was synthesized using the same 
method as described for triazole 16 (Scheme 5). 
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Scheme 5. Reagents and conditions. (a) 1-chloro-4-ethynylbenzene, CuSO4·5H2O, sodium 
ascorbate, H2O/t-BuOH 2:1, rt, 4 d, 31%. 
The synthesis of 3’-modified α-thymidine analogue 21 started with the anomerisation of 5’-O-
acetylated AZT 36.13 Deprotection of 37 followed by CuAAC with 1-chloro-4-ethynylbenzene afforded 
triazole 21 in moderate yield (Scheme 6). 
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Scheme 6. Reagents and conditions: (a) acetic anhydride, H2SO4, CH2Cl2, rt, 2 h, 20% (b) 7N NH3 
in MeOH, rt, overnight, 72%, (c) 1-chloro-4-ethynylbenzene, CuSO4·5H2O, sodium ascorbate, H2O/t-
BuOH 1:3, rt, 24 h, 47%. 
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Table 1. Kinetic Parameters of TMPKmt with Compounds 3-22. 
O
OH
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N
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14-16 3, 17-20 21-224-13  
Compound X R Ki (μM) TMPKmt 
Ki (μM) 
TMPKh 
SI (Ki TMPKh/ 
Ki TMPKmt) 
MIC99          
M. bovis 
(μg/mL) 
3 O 3-CF3-4-Cl-phenylthiourea 0.6    
4 O 3-CF3-4-Cl-phenylurea 2.8 95 34  
5 O 3-CF3-4-Cl-phenylthiourea 9.9    
6 (AZT) O N3 28    
7 S N3 ≥ 100    
8 O 4-(Phenyl)-triazol-1-yl 4.2    
9 O 4-(p-Chlorophenyl)-triazol-1-yl 2.1    
10 S 4-(p-Chlorophenyl)-triazol-1-yl 15    
11 O 4-(Benzyl)-triazol-1-yl 2.7 N.I.b > 100  
12 O 1-(3-CF3-4-Cl-phenyl)-tetrazol-5-amine 45    
13 O 5-(Aminobenzyl)-tetrazol-1-yl 2.3 N.I.b > 100  
14 O 3-CF3-4-Cl-phenylthiourea 14.5    
15 O 1-(3-CF3-4-Cl-phenyl)-tetrazol-5-amine 73    
16 O 4-(p-Chlorophenyl)-triazol-1-yl 201    
17 O N3 26.5    
18 S Phenylthiourea N. I.a    >> 100 
19 S 3-CF3-4-Cl-phenylthiourea 0.17 N.I.a > 100 25  
20 O 4-(p-Chlorophenyl)-triazol-1-yl 9    
21 O N3 6    
22 O 4-(p-Chlorophenyl)-triazol-1-yl 35    
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N.I.: no inhibition detected at a final concentration of (a) 0.05 mM and (b) 1 mM. 
 
2.1 Biological evaluation 
All compounds have been evaluated for TMPKmt inhibition as described in the Experimental Section 
and results are summarized in Table 1. Replacement of the 3’-azido group of AZT (6) by a 3-CF3-4-Cl-
phenylurea substituent (4) resulted in a 10-fold increased activity, while this trend was less 
pronounced with the thiourea analogue 5. In the 1,4-substituted 1,2,3-triazole series, the anti-TMPKmt 
activity was clearly influenced by the nature of the substituent at C-4 of the triazole. The click product 
of AZT and phenylacetylene (8) proved to be more potent than AZT itself. p-Chloro-substitution of the 
phenyl ring of 8 or introduction of a methylene between the triazole and the phenyl caused a moderate 
increase in activity (11). In this series of 3’-modified thymidine analogues, replacement of the oxygen 
at position 4 of the thymine moiety by a sulfur typically led to a significant drop in affinity for the target 
enzyme (compare couples 6/7 and 9/10). Compounds 12 and 13, both containing a 1,5-disubstituted 
tetrazole, significantly differed in their capacity to inhibit TMPKmt. The aminotetrazole analogue 13, in 
which the tetrazole ring is directly attached to the sugar ring, showed a significantly better activity 
compared to analogue 12 in which the tetrazole ring is connected to C-3’ via a NH-bridge. 
Remarkably, an opposite trend was observed for these tetrazole analogues on mitochondrial 
thymidine kinase 2.11 
The inhibitory activity of a series of 5’-modified β-thymidine analogues appeared to be weak. 
Introduction of a 3-CF3-4-Cl-phenylthiourea substituent (14) gave micromolar inhibition, while 
replacement of the thiourea by a 1-(3-CF3-4-Cl-phenyl)-tetrazol-5-amine (15) or a 4-(p-chlorophenyl)-
triazol-1-yl (16) caused a 5 and 14-fold drop in Ki value, respectively. Comparison of the anomeric 
couples 3/14 and 16/20 demonstrate that the α-anomers, which feature a trans orientation of the 
nucleobase and the 5’-substituent, exhibit superior TMPKmt inhibition compared to their β-epimers 
(factor 22-24). 
The 5’-modified α-thymidine analogues (3, 17-20) demonstrated moderate to excellent inhibitory 
activity for TMPKmt. Also in this small series, the activity is influenced by the nature of the substituent 
at the 5’-position. Derivative 17, containing an azide function, gave moderate inhibition with a strikingly 
comparable Ki value (26.5 μM) as its AZT counterpart (28 μM). As observed in the 3’-modified β-
series, conversion of the 5’-azide moiety by a 4-(p-chlorophenyl)-1,2,3-triazol-1-yl substituent 
improved the inhibitory activity, although to a lesser extent. Most interestingly and in contrast to what 
was observed in the 3’-modified β-series, substitution of the 4-O of the original hit 3 by a 4-S, 
increased the activity by a factor 3, ranking compound 19 amongst the most potent TMPKmt inhibitors 
together with the (Z)-butenylthymines with a naphtholactam or naphthosultam moiety at position 4 (Ki 
values of 0.42 and 0.27 µM, respectively).19  
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In addition, α-analogue 22, which was synthesized to further assess the influence of the relative 
orientation between the aryl moiety and the nucleobases, showed poor inhibitory activity against 
TMPKmt, indicating that the preferred trans-orientation of the base and the aromatic substituent also 
holds for the 3’-modified analogues.  
Compound 19 was evaluated for its in vitro inhibitory activity against Mycobacterium bovis BCG. It 
showed 100% inhibition of bacterial growth at a concentration of 25 μg/mL. 
In an effort to rationalize the 3-fold increase in affinity upon replacement of the 4-O of the original hit 3 
by a 4-S (19), both compound were docked into the substrate binding site of the TMPKmt enzyme 
(Figure 2).8 The interactions of the base moiety with the surrounding residues is in inhibitor 3 are 
similar to the ones with the natural substrate6: a stacking with Phe70, H-bond of base atom N3 with 
Asn100 and base atom O4 hydrogen bonding with Arg74. An additional hydrogen bond involving O3' 
and Tyr39 may explain the better activity of 3 compared to its 3’-deoxygenated analogue.8 In 
compound 19 where the C(4)=O at is replaced by a C(4)=S, the hydrogen bonds to Arg74 is lost. 
However, due to the bigger size of the sulfur atom, a better van der Waals interaction is seen with 
surrounding residues Phe70, Arg74 and Asn100 which may explain a higher affinity for this inhibitor. 
  
Figure 2. Compound 3 (a) and compound 19 (b) docked in the substrate binding site of TMPKmt. The 
carbon atoms of both inhibitors are colored green. The enzyme contact surface is colored cyan, and 
the contact surface with the 4S atom is colored magenta. 
3. Conclusions 
On the basis of the structures of nucleosides 2 and 3, which were identified earlier as potent TMPKmt 
inhibitors, this paper describes the synthesis and biological evaluation of a series of new thymidine 
analogues, including α- and β-derivatives. In both the 3’- and the 5’-derivatised analogues, the anomer 
that places the thymine base trans to the aromatic substituent showed the best TMPKmt inhibition. In 
addition, several analogues were synthesized in which the 4-oxygen was replaced by a more lipophilic 
sulphur atom to probe the influence of this modification on TMPKmt inhibitory activity. Remarkably, a 
4-thio modification of the pyrimidine base was favorable for the 5’-modified α-analogues, while it 
caused an opposite effect the 3’-modified β-analogues. Several compounds showed an inhibitory 
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potency in the low micromolar range, with the 5’-arylthiourea 4-thio-α-thymidine analogue 19 being the 
most active one (Ki = 0.17 μM). This compound is capable of inhibiting M. bovis at a concentration of 
25 μg/mL, promoting TMPKmt as an attractive target for further inhibitor design. 
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4. Experimental Section 
Spectrophotometric Binding Assay. TMPKmt activities were determined using the coupled 
spectrophotometric assay described by Blondin et al.20
Ki  =
Km  [ I ]
(        - 1 ) ( Km + [ S ] )vvi
(Eq.1)
 using an Eppendorf ECOM 6122 photometer 
and a wavelength of 334 nm. The reaction medium (0.5 mL final volume) contained 50 mM Tris-HCl, 
pH 7.4, 50 mM KCl, 2 mM MgCl2, 0.2 mM NADH, 1 mM phosphoenol pyruvate, and 2 units each of 
lactate dehydrogenase, pyruvate kinase, and nucleoside diphosphate kinase. The concentrations of 
ATP and dTMP were kept constant at 0.5 and 0.05 mM, respectively, whereas the concentrations of 
analogues varied between 0.003 and 1.5 mM. Equation 1 was used to calculate the Ki values using 
Equations 2 and 3 (classical competitive inhibition model following the Lineweaver-Burk 
representation): 
v  =
Vm [ S ]
[ S ] + Km
(Eq.2) vi  =
Vm [ S ]
[ S ] + Km ( 1 +         )
[ I ]
Ki
(Eq.3)
 
where v and vi are the reaction velocities respectively in the absence and in the presence of the 
analogue at a concentration value [I]; Km is the Km for dTMP (4.5 µM for TMPKmt and 5 µM for 
TMPKh); [S] is the concentration of dTMP (50 µM). For each compound, vi determinations were 
performed at least at two different concentration values [I]. 
Biological Assays on Mycobacterium bovis (BCG). Compounds 18 and 19 were assayed for their 
inhibitory potency on Mycobacterium bovis var. BCG growth in vitro.21 A micro-method of culture was 
performed in 7H9 Middlebrook broth medium containing 0.2% glycerol and 0.5% Tween-80. Serial 2-
fold dilutions of each compound were prepared directly in 96-well plates. The bacterial inoculum was 
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prepared previously at a concentration in the range of 107 bacteria (M. bovis BCG 1173P2) in 7H9 
medium and stored at -80 °C until used. The bacteria, adjusted at 105 per mL, were delivered in 100 
μL per well. The covered plates were sealed with parafilm and incubated at 37 °C in plastic boxes 
containing a humidified normal atmosphere. At day 8 of incubation, 30 μL of a resazurin (Sigma) 
solution at 0.01% (wt/vol) in water was added to each well. After an overnight incubation at 37 °C, the 
plates were assessed for color development using the optical density difference at 570 and 630 nm on 
a microplate reader. The change from blue to pink indicates reduction of resazurin and therefore 
bacterial growth. The lowest compound concentration that prevented the color change determined the 
MIC for the assayed compound. 
Synthesis. General. All reagents were from standard commercial sources and of analytical grade. 
Precoated Merck silica gel F254 plates were used for TLC, spots were examined under ultraviolet light 
at 254 nm and further visualized by sulfuric acid-anisaldehyde spray. Column chromatography was 
performed on silica gel (63-200 μm, 60 Å, Biosolve, Valkenswaard, The Netherlands). NMR spectra 
were determined using a Varian Mercury 300 MHz spectrometer. Chemical shifts are given in ppm (δ) 
relative to the residual solvent peak: in the case of DMSO-d6, it is 2.54 ppm for 1H and 40.5 ppm for 
13C; in the case of CDCl3, it is 7.26 ppm for 1H and 77.4 ppm for 13C. Structural assignment was 
confirmed with COSY and DEPT. All signals assigned to hydroxyl groups were exchangeable with 
D2O. Exact mass measurements were performed on a Waters LCT Premier XETM Time of flight 
(TOF) mass spectrometer equipped with a standard electrospray ionization (ESI) and modular 
LockSpray TM interface. Samples were infused in a CH3CN/water (1:1) mixture at 10 μL/min.  
5’-O-Acetyl-3’-azido-3’-deoxy-4-thio-β-D-thymidine (24). Lawesson’s reagent (154 mg, 0.38 mmol) 
was added to a solution of compound 23 (111 mg, 0.36 mmol) in 10 mL anhydrous toluene. The 
mixture was refluxed overnight and the solvent was removed in vacuo. The residue was purified by 
column chromatography (CH2Cl2/ MeOH 95:5) to give compound 24 as a brown-yellow solid (23 mg, 
20%). 1H NMR (300 MHz, DMSO-d6): δ 1.99 (3H, d, J= 0.9 Hz, 5-CH3), 2.06 (3H, s, OAc), 2.34-2.43 
(1H, m, H-2’a), 2.53-2.57 (1H, m, H-2’b), 3.99-4.04 (1H, m, H-4’), 4.21-4.32 (2H,m, H-5’a an H-5’b), 
4.44-4.50 (1H, m, H-3’), 6.07 (1H, dd, J= 5.7 Hz, J= 7.2 Hz, H-1’), 7.58 (1H, s, H-6), 12.75 (1H, s, 3-
NH). 13C NMR (75 MHz, DMSO-d6): δ 16.78 (5-CH3), 20.58 (OAc), 35.96 (C-2’), 59.81 (C-3’), 63.09 
(C-5’), 81.10 (C-4’), 84.64 (C-1’), 117.95 (C-5), 133.32 (C-6), 147.67 (C-2), 171.92 (OAc), 190.95 (C-
4). Exact mass (ESI-MS) for C12H16N5O4S [M+H]+ found, 326.0941; calcd, 326.0918.  
3’-Azido-3’-deoxy-4-thio-β-D-thymidine (7). Compound 24 (16 mg, 0.050 mmol) was dissolved in a 
7N NH3 in MeOH solution (1 mL) and stirred at room temperature for 6 hours. The reaction mixture 
was concentrated in vacuo and the residue was purified on a silica gel column using CH2Cl2/MeOH 
(95:5) as the eluent to afford compound 7 as a yellow powder (6.0 mg, 42%). 1H NMR (300 MHz, 
DMSO-d6): δ 1.97 (3H, d, J= 0.6 Hz, 5-CH3), 2.29-2.38 (1H, m, H-2’a), 2.41-2.48 (1H, m, H-2’b), 3.59-
3.71 (2H, m, H-5’a and H-5’b), 3.83-3.87 (1H, m, H-4’), 4.40 (1H, app dd, J= 6.0 Hz, J= 12.6 Hz, H-3’), 
5.28 (1H, br s, 5’-OH), 6.04 (1H, app t, J= 5.7 Hz, H-1’), 7.86 (1H, s, H-6). 13C NMR (75 MHz, DMSO-
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d6): δ 16.90 (5-CH3), 36.64 (C-2’), 59.44 (C-3’), 60.35 (C-5’), 84.32 and 84.44 (C-4’ and C-1’), 117.63 
(C-5), 133.34 (C-6), 147.71 (C-2), 190.76 (C-4). Exact mass (ESI-MS) for C10H14N5O3S [M+H]+ found, 
326.284.0813; calcd, 284.0812. Spectroscopic data of 7 were in accordance with literature data.22
5’-O-acetyl-3’-(4-chlorophenyl-1,2,3-triazol-1-yl)-3’-deoxy-β-D-thymidine (25). Compound 23 (146 
mg, 0.47 mmol), sodium ascorbate (5 mg, 0.024 mmol) and CuSO4͘͘ ·5H2O (5 mg, 0.019 mmol) were 
suspended in 9 mL of H2O/t-BuOH (2:1). 1-Chloro-4-ethynylbenzene (129 mg, 0.94 mmol) was added 
after 15 minutes and the mixture was stirred at room temperature for 24 h. The reaction mixture was 
extracted with EtOAc and the combined organic phases were dried over anhydrous MgSO4 and 
evaporated to anhydrousness. The crude product was purified column chromatography (CH2Cl2/MeOH 
95:5) affording 25 (87 mg, 41 %) as a white powder. 1H NMR (300 MHz, DMSO-d6): δ 1.84 (3H, s, 5-
CH3), 2.04 (3H, s, OAc), 2.73-2.94 (2H, m, H-2’a and H-2’b), 4.27-4.37 (2H, m, H-5’a and H-5’b), 4.43-
4.49 (1H, m, H-4’), 5.47-5.54 (1H, m, H-3’), 6.45 (1H, t, J= 7.2 Hz, H-1’), 7.52-7.57 (2H, m, subs Ph), 
7.63 (1H, d, J= 1.2 Hz, H-6), 7.85-7.90 (2H, m, subs Ph), 8.86 (1H, s, H-5”), 11.41 (1H, s, 3-NH). 13C 
NMR (75 MHz, DMSO-d6): δ 12.14 (5-CH3), 20.53 (OAc), 36.36 (C-2’), 59.50 and 63.29 (C-5‘ and C-
3’), 80.85 (C-4’), 84.15 (C-1’), 110.00 (C-5), 121.34 (C-5”), 126.86, 129.07, 129.42 and 132.48 (subs 
Ph), 136.39 (C-6), 145.54 (C-4”), 150.44 (C-2), 163.74 (C-4), 170.08 (OAc). Exact mass (ESI-MS) for 
C20H21ClN5O5 [M+H]+ found, 446.1238; calcd, 446.1226. 
 
5’-O-acetyl-3’-(4-chlorophenyl-1,2,3-triazol-1-yl)-3’-deoxy-4-thio-β-D-thymidine (26). Lawesson’s 
reagent (158 mg, 0.39 mmol) was added to a solution of compound 25 (87 mg, 0.20 mmol) in 10 mL 
anhydrous toluene. The mixture was refluxed overnight and the solvent was removed in vacuo. The 
residue was purified by column chromatography (CH2Cl2/ MeOH 95:5) to give compound 26 as a 
brown-yellow solid (44 mg, 49%). 1H NMR (300 MHz, CDCl3): δ 2.00 (3H, s, 5-CH3), 2.05 (3H, s, OAc), 
2.86-2.94 (1H, m, H-2’a), 3.17-3.26 (1H, m, H-2’b), 4.35 (2H, d, J= 3.3 Hz, H-5’a and H-5’b), 4.59-4.65 
(1H, m, H-4’), 5.49 (1H, app dd, J= 7.5 Hz, J= 15.3 Hz, H-3’),6.01-6.04 (1H, m, H-1’), 7.24 (1H, s, H-6), 
7.32 (2H, d, J= 8.4 Hz, subs Ph), 7.68 (2H, d, J= 8.4 Hz, subs Ph), 7.93 (1H, s, H-5”), 11.10 (1H, s, 3-
NH). 13C NMR (75 MHz, CDCl3): δ 17.41 (5-CH3), 21.00 (OAc), 38.16 (C-2’), 60.31 and 63.45 (C-5‘ 
and C-3’), 82.99 (C-4’), 89.57 (C-1’), 120.21 and 120.71 (C-5 and C-5”), 127.23, 128.77, 129.39, 
134.01 and 134.47 (C-6 and subs Ph), 147.20 and 148.49 (C-4” and C-2), 170.66 (OAc), 190.91 (C-4). 
Exact mass (ESI-MS) for C20H21ClN5O4S [M+H]+ found, 462.1042; calcd, 462.0997. 
3’-(4-Chlorophenyl-1,2,3-triazol-1-yl)-3’-deoxy-4-thio-β-D-thymidine (10). Compound 26 (42 mg, 
0.090 mmol) was dissolved in a 7N NH3 in MeOH solution (1 mL) and stirred at room temperature for 6 
hours. The reaction mixture was concentrated in vacuo and the residue was purified on a silica gel 
column using CH2Cl2/MeOH (95:5) as the eluent to afford compound 10 as a yellow powder (25.2 mg, 
66%). 1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, d, J= 0.9 Hz, 5-CH3), 1.96 (1H, app dt, J= 3.6 Hz, J= 
14.1 Hz, H-2’a), 2.45-2.55 (1H, m, H-2’b), 4.28 (1H, app s, H-3’), 4.47-4.64 (3H, m, H-4’, H-5’a and H-
5’b), 5.63 (1H, s, 5’-OH), 6.18 (1H, dd, J= 3.9 Hz, J= 7.5 Hz, H-1’), 7.49-7.54 (2H, m, subs Ph), 7.72 
(1H, d, J= 1.2 Hz, H-6), 7.86-7.91 (2H, m, subs Ph), 8.62 (1H, s, H-5”). 13C NMR (75 MHz, DMSO-d6): 
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δ 16.94 (5-CH3), 37.51 (C-2’), 59.02 (C-3’), 60.41 (C-5‘), 84.80 and 84.90 (C-4’ and C-1’), 117.81 (C-
5), 121.40 (C-5”), 126.87, 129.03, 129.47, 132.44 and 133.50 (C-6 and subs Ph), 145.49 and 147.79 
(C-4” and C-2), 190.90 (C-4). Exact mass (ESI-MS) for C18H19ClN5O3S [M+H]+ found, 420.0915; calcd, 
420.0892. 
N-(5’-Deoxy-3’-O-tert-butyldimethylsilyl-β-D-thymidin-5’-yl)-N’-(4-chloro-3-trifluoromethyl-
phenyl)-thiourea (28). To a solution of compound 27 (403 mg, 1.13 mmol) in DMF (4 mL) was added 
a solution of 4-chloro-3-(trifluoromethyl)phenylisothiocyanate (0.18 mL, 1.13 mmol) in DMF (2 mL) at 0 
°C. The reaction mixture was stirred for 1 h. The solvents were evaporated to anhydrousness and the 
residue was purified by column chromatography (CH2Cl2/MeOH 98:2) affording compound 28 as a 
colorless solid (510 mg, 76%). 1H NMR (300 MHz, DMSO-d6): δ 0.098 (6H, s, TBDMS), 0.87-0.88 (9H, 
m, TBDMS), 1.80 (3H, s, 5-CH3), 2.02-2.10 (1H, m, H-2’a), 2.24-2.34 (1H, m, H-2’b), 3.55-3.65 (1H, m, 
H-4’), 3.98-3.99 (2H, m, H-5’a and H-5’b), 4.45-4.47 (1H, m, H-3’), 6.15-6.19 (1H, m, H-1’), 7.52 (1H, 
s, subs Ph), 7.62-7.72 (2H, m, subs Ph and H-6), 7.96 (1H, subs Ph), 8.12 (1H, s, 5’-NH), 9.93 (1H, s, 
N’H), 11.33 (1H, s, 3-NH). 13C NMR (75 MHz, DMSO-d6): δ -4.99 and -4.93 (TBDMS), 11.95 (5-CH3), 
17.57 (TBDMS), 25.57 (TBDMS), C-2’ (under solvent peak), 45.74 (C-5’), 72.80 (C-3’), 83.98 and 
84.19 (C-1’ and C-4’), 109.74 (C-5), 124.50-139.00 (subs Ph, CF3 and C-6), 150.36 (C-2), 163.56 (C-
4), 180.77 (C=S). Exact mass (ESI-MS) for C24H33ClF3N4O4Si [M+H]+ found, 593.1643; calcd, 
593.1627. 
N-(5’-Deoxy-β-D-thymidin-5’-yl)-N’-(4-chloro-3-trifluoromethylphenyl)-thiourea (14). Compound 
28 (84 mg, 0.14 mmol) was dissolved in THF (0.9 mL). A solution of 1M tetra-n-
butylammoniumfluoride in THF (0.31 mL) was added. After 1 h at room temperature the reaction was 
completed. The solvent was evaporated and the anhydrous residue was purified by column 
chromatography (CH2Cl2/MeOH 95:5) to give pure compound 14 (40 mg, white solid) in 60% yield. 1H 
NMR (300 MHz, DMSO-d6): δ 1.79 (3H, s, 5-CH3), 2.05-2.13 (1H, m, H-2’a), 2.17-2.27 (1H, m, H-2’b), 
3.59-3.66 (1H, m, H-4’), 3.87-3.96 (2H, m, H-5’a and H-5’b), 4.23-4.24 (1H, m, H-3’), 5.38 (1H, d, J= 
4.2 Hz, 3’-OH), 6.18-6.22 (1H, m, H-1’), 7.51-7.7.75 (3H, m, subs Ph and H-6), 8.17-8.22 (2H, m, subs 
Ph and 5’-NH), 9.99 (1H, s, N’H), 11.32 (1H, s, 3-NH). 13C NMR (75 MHz, DMSO-d6): δ 12.73 (5-CH3), 
C-2’ (under solvent peak), 46.95 (C-5’), 71.97 (C-3’), 84.56 and 84.69 (C-1’ and C-4’), 110.54 (C-5), 
121.59-139.91 (subs Ph, CF3 and C-6), 151.18 (C-2), 164.38 (C-4), 181.44 (C=S). Exact mass (ESI-
MS) for C18H19ClF3N4O4 [M+H]+ found, 479.0778; calcd, 479.0762. 
5-(5’-Amino-5’-deoxy-3’-O-tert-butyldimethylsilyl-β-D-thymidin-5’N-yl)-1-(4-chloro-3-trifluoro-
methylphenyl)-tetrazole (29). To a suspension of compound 28 (504 mg, 0.85 mmol), sodium azide 
(166 mg, 2.55 mmol) and HgCl2 (253 mg, 0.93 mmol) in anhydrous DMF (3.3 mL) was added Et3N 
(0.36 mL, 2.55 mmol) under N2 atmosphere. The resulting black suspension was stirred overnight at 
room temperature. The mixture was filtered through a pad of Celite, washing with CH2Cl2. The filtrate 
was diluted with water and extracted with CH2Cl2. The combined organic layers were dried over 
MgSO4, filtered and concentrated under reduced pressure. The resulting residue was purified by silica 
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gel chromatography (CH2Cl2/MeOH 98:2) affording compound 29 (424 mg, 83%) as a colorless solid. 
1H NMR (300 MHz, DMSO-d6): δ 0.029-0.042 (6H, m, TBDMS), 0.84-0.86 (9H, m, TBDMS), 1.78 (3H, 
s, 5-CH3), 2.00-2.07 (1H, m, H-2’a), 2.23-2.33 (1H, m, H-2’b), 3.48-3.62 (2H, m, H-5’a and H-5’b), 
3.94-3.99 (1H, m, H-4’), 4.42-4.45 (1H, m, H-3’), 6.10-6.14 (1H, m, H-1’), 7.41 (1H, t, J= 6.0 Hz, 5’-
NH), 7.53 (1H, d, J= 1.2 Hz, H-6), 7.88-8.03 (3H, m, subs Ph), 11.31 (1H, s, 3-NH). 13C NMR (75 MHz, 
DMSO-d6): δ -5.06 and -4.91 (TBDMS), 11.92 (5-CH3), 17.56 (TBDMS), 25.56 (TBDMS), C-2’ (under 
solvent peak), 45.82 (C-5’), 72.90 (C-3’), 84.07 and 84.58 (C-1’ and C-4’), 109.61 (C-5), 128.00-
136.27 (subs Ph, CF3 and C-6), 150.35 (C-2), 155.28 (C=N), 163.62 (C-4). Exact mass (ESI-MS) for 
C24H32ClF3N7O4Si [M+H]+ found, 602.1910; calcd, 602.1920. 
5-(5’-Amino-5’-deoxy-β-D-thymidin-5’N-yl)-1-(4-chloro-3-trifluoromethylphenyl)-tetrazole (15). 
Compound 29 (241 mg, 0.400 mmol) was dissolved in THF (2.5 mL). A solution of 1 M tetra-n-
butylammoniumfluoride in THF (0.88 mL) was added. After 1 h at room temperature the reaction was 
completed. The solvent was evaporated and the anhydrous residue was purified by column 
chromatography (CH2Cl2/MeOH 95:5) to give pure compound 15 (104 mg, white solid) in 53% yield. 1H 
NMR (300 MHz, DMSO-d6): δ 1.76 (3H, d, J= 0.9 Hz, 5-CH3), 2.04-2.11 (1H, m, H-2’a), 2.14-2.24 (1H, 
m, H-2’b), 3.49-3.65 (2H, m, H-5’a and H-5’b), 3.93-3.98 (1H, m, H-4’), 4.22-4.27 (1H, m, H-3’), 5.32 
(1H, d, J= 4.5 Hz, 3’-OH), 6.12-6.17 (1H, m, H-1’), 7.39 (1H, t, J= 5.7 Hz, 5’-NH), 7.50 (1H, d, J= 1.5 
Hz, H-6), 7.90-8.07 (3H, m, subs Ph), 11.29 (1H, s, 3-NH). 13C NMR (75 MHz, DMSO-d6): δ 12.02 (5-
CH3), C-2’ (under solvent peak), 46.16 (C-5’), 71.24 (C-3’), 83.91 (C-1’), 84.28 (C-4’), 109.73 (C-5), 
124.95-136.26 (subs Ph, CF3 and C-6), 150.47 (C-2), 155.42 (C=N), 163.76 (C-4). Exact mass (ESI-
MS) for C18H18ClF3N7O4 [M+H]+ found, 488.1052; calcd, 488.1055. 
5’-(4-Chlorophenyl-1,2,3-triazol-1-yl)-5’-deoxy-β-D-thymidine (16). Compound 30 (56 mg, 0.21 
mmol), sodium ascorbate (cat. amount) and CuSO4͘͘ ·5H2O (cat. amount) were suspended in 3 mL of 
H2O/t-BuOH (1:2). 1-Chloro-4-ethynylbenzene (57 mg, 0.42 mmol) was added after 15 minutes and 
the mixture was stirred at room temperature for 7 days. The reaction mixture was extracted with 
EtOAc and the combined organic phases were dried over anhydrous MgSO4 and evaporated to 
anhydrousness. Purification of the crude using RP-HPLC (Phenomenex Luna C-18, H2O/0.1% 
HCOOH in CH3CN, 90:10 → 0:100 in 23 min, flow 17.5 mL/min) afforded compound 16 (2.0 mg, 2%) 
as a white powder. 1H NMR (300 MHz, DMSO-d6): δ 1.68 (3H, s, 5-CH3), 2.02-2.24 (2H, m, H-2’a and 
H-2’b), 4.09-4.14 (1H, m, H-4’), 4.28-4.31 (1H, m, H-3’), 4.64-4.80 (2H, m, H-5’a and H-5’b), 5.59 (1H, 
br s, 3’-OH), 6.18 (1H, app t, J= 6.9 Hz, H-1’), 7.23 (1H, d, J= 1.2 Hz, H-6), 7.49-7.53 (2H, m, subs 
Ph), 7.85-7.90 (2H, m, subs Ph), 8.62 (1H, s, H-5”), 11.30 (1H, s, 3-NH). 13C NMR (75 MHz, DMSO-
d6): δ 11.96 (5-CH3), 37.84 (C-2’), 51.13 (C-5’), 70.47 (C-3’), 83.66 (C-4’), 83.77 (C-1’), 109.79 (C-5), 
122.53-132.25 (subs Ph and C-5”), 135.96 (C-6), 145.26 (C-4”), 150.37 (C-2), 163.56 (C-4). Exact 
mass (ESI-MS) for C18H19ClN5O4 [M+H]+ found, 404.1125; calcd, 404.1120.  
4-Thio-α-D-thymidine (33). Lawesson’s reagent (777 mg, 1.92 mmol) was added to a solution of 
compound 3’-5’-di-O-acetyl-α-D-thymidine (31) (519 mg, 1.59 mmol) in 15 mL anhydrous 1,4-dioxane. 
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The mixture was refluxed for 4 hours. After the reaction mixture had been cooled, the solvent was 
removed in vacuo. The crude product thus obtained was treated with 8 mL of a 7N NH3 in MeOH 
solution and stirred at room temperature for 4 hours. The reaction mixture was concentrated in vacuo 
and the residue was purified on a silica gel column using CH2Cl2/MeOH (94:6) as the eluent to afford 
compound 33 as a yellow foam (150 mg, 37%). 1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, s, 5-CH3), 
1.94-1.98 (1H, m, H-2’a), 2.51-2.57 (1H, m, H-2’b), 3.40 (2H, t, J= 5.2 Hz, H-5’a and H-5’b), 4.23-4.25 
(2H, m, H-3’ and H-4’), 4.86 (1H, t, J= 5.7 Hz, 5’-OH), 5.26 (1H, d, J= 2.7 Hz, 3’-OH), 6.04 (1H, dd, J= 
2.7 Hz, J= 7.5 Hz, H-1’), 7.81 (1H, d, J= 0.9 Hz, H-6), 12.65 (1H, s, 3-NH). Exact mass (ESI-MS) for 
C10H15N2O4S [M+H]+ found, 259.0753; calcd, 259.0747.  
5’-O-Methanesulfonyl-4-thio-α-D-thymidine (34). To a solution of 4-thio-α-D-thymidine 33 (146 mg, 
0.57 mmol) in pyridine (5 mL) at -78 °C, methanesulfonylchloride (42 μL,0.54 mmol) was added. The 
reaction mixture was stirred for 1 h at 0 °C. The reaction was quenched with saturated aqueous 
NaHCO3-solution and extracted with CH2Cl2 three times, dried over MgSO4 and evaporated. The 
residue was purified by column chromatography (CH2Cl2/ MeOH 95:5) to give mesylated compound 34 
as a yellow foam (133 mg, 70%). 1H NMR (300 MHz, DMSO-d6): δ 1.97 (3H, d, J= 0.6 Hz, 5-CH3), 
1.99-2.04 (1H, m, H-2’a), 2.53-2.30 (1H, m, H-2’b), 3.22 (3H, s, SO2CH3), 4.08-4.10 (2H, m, H-5’a and 
H-5’b), 4.16-4.30 (1H, m, H-3’), 4.40-4.46 (1H, m, H-4’), 5.55 (1H, br s, 3’-OH), 6.09 (1H, dd, J= 3.6 
Hz, J= 7.5 Hz, H-1’), 7.69 (1H, s, H-6). Exact mass (ESI-MS) for C11H17N2O6S2 [M+H]+ found, 
337.0533; calcd, 337.0523. 
5’-Azido-5’-deoxy-4-thio-α-D-thymidine (35). A solution of 5’-mesylated 4-thio-α-D-thymidine 34 
(129 mg, 0.38 mmol) and NaN3 (250 mg, 3.86 mmol) in DMF (7 mL) was heated to 60 °C overnight. 
The reaction mixture was evaporated in vacuo. The residue was resolved in CH2Cl2 and washed with 
brine. The organic layer was dried over MgSO4, evaporated and purified by column chromatography 
(CH2Cl2/MeOH 95:5) to afford compound 35 (97 mg, 89%) as a yellow oil. 1H NMR (300 MHz, DMSO-
d6): δ 1.98 (3H, d, J= 0.9 Hz, 5-CH3), 2.04 (1H, t, J= 3.3 Hz, H-2’a), 2.56-2.65 (1H, m, H-2’b), 3.40-
3.44 (2H, m, H-5’a and H-5’b), 4.14-4.17 (1H, m, H-3’), 4.34-4.39 (1H, m, H-4’), 5.47 (1H, br s, 3’-OH), 
6.09 (1H, dd, J= 3.6 Hz, J= 7.5 Hz, H-1’), 7.78 (1H, s, H-6). Exact mass (ESI-MS) for C10H14N5O3S 
[M+H]+ found, 284.0813; calcd, 284.0812. 
5’-Amino-5’-deoxy-4-thio-α-D-thymidine (36). Compound 35 (97 mg, 0.34 mmol) and PPh3 (187 mg, 
0.71 mmol) were dissolved in THF (6 mL). After stirring for 10 minutes, H2O was added (883 μL) and 
the mixture was stirred for 1 day. The mixture was extracted with CH2Cl2 and the water phase 
lyophilized to give amine 36 (78 mg, 89%). 1H NMR (300 MHz, DMSO-d6): δ 1.96 (3H, d, J= 0.6 Hz, 5-
CH3), 2.00 (1H, t, J= 3.6 Hz, H-2’a), 2.58-2.68 (1H, m, H-2’b), 2.76-2.87 (1H, m, H-5’a), 2.96-3.04 (1H, 
m, H-5’b), 4.18-4.20 (1H, m, H-3’), 4.32 (1H,dt, J= 3.3 Hz, J= 9.6 Hz, H-4’), 5.57 (1H, br s, 3’-OH), 6.15 
(1H, dd, J= 3.3 Hz, J= 7.5 Hz, H-1’), 7.77 (1H, s, H-6). Exact mass (ESI-MS) for C10H16N3O3S [M+H]+ 
found, 258.0907; calcd, 258.0907. 
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N-(5’-Deoxy-4-thio-α-D-thymidin-5‘-yl)-N’-phenylthiourea (18). For the synthesis of compound 18, 
amine 36 (26 mg, 0.10 mmol) was dissolved in DMF (1 mL). At 0 °C, phenyl isothiocyanate (16 mg, 
0.12 mmol) was added and the reaction mixture was allowed to stir at room temperature during 3 h. 
After completion of the reaction, the reaction mixture was evaporated to anhydrousness and the 
residue was purified by column chromatography (CH2Cl2/MeOH 95:5) to obtain the pure final 
compound 18 (27.0 mg, 69%) as a yellow powder. 1H NMR (300 MHz, DMSO-d6): δ 1.97 (3H, d, J= 
0.9 Hz, 5-CH3), 2.01-2.03 (1H, m, H-2’a), 2.54-2.63 (1H, m, H-2’b), 3.53-3.70 (2H, m, H-5’a and H-
5’b), 4.21-4.24 (1H, m, H-3’), 4.42-4.46 (1H, m, H-4’), 5.43 (1H, d, J= 2.7 Hz, 3’-OH), 6.12 (1H, dd, J= 
2.7 Hz, J= 7.5 Hz, H-1’), 7.08-7.13 (1H, m, Ph), 7.29-7.34 (2H, m, Ph), 7.43-7.47 (2H, m, Ph), 7.80 
(1H, s, H-6). 13C NMR (75 MHz, DMSO-d6): δ 17.03 (5-CH3), under DMSO (C-2’), 45.49 (C-5’), 70.79 
(C-3’), 86.08 (C-1’), 86.78 (C-4’), 117.22 (C-5), 123.22, 124.30, 128.63 and 134.25 (Ph), 139.13 (C-6), 
147.87 (C-2), 180.74 (C=S), 190.56 (C-4). Exact mass (ESI-MS) for C17H21N4O3S2 [M+H]+ 
found,393.1053; calcd, 393.1050. 
N-(5’-Deoxy-4-thio-α-D-thymidin-5‘-yl)-N’-(3-trifluoromethyl-4-chlorophenyl)thiourea (19). 
Compound 19 was synthesized from amine 36 (52 mg, 0.20 mmol) and 4-chloro-3-
trifluoromethylphenyl isothiocyanate (57 mg,0.24 mmol) using the same procedure as described for 
the synthesis of compound 18. After purification by column chromatography (CH2Cl2/MeOH 95:5), 
compound 19 (41.7mg, 42%) was obtained as a yellow powder. 1H NMR (300 MHz, DMSO-d6): δ 1.98 
(3H, d, J= 0.6 Hz, 5-CH3), 2.06 (1H, t, J= 2.1 Hz, H-2’a), 2.57-2.66 (1H, m, H-2’b), 3.56-3.59 (1H, m, 
H-5’a), 3.67-3.72 (1H, m, H-5’b), 4.25-4.26 (1H, m, H-3’), 4.44-4.48 (1H, m, H-4’), 5.47 (1H, d, J= 3.0 
Hz, 3’-OH), 6.14 (1H, dd, J= 2.7 Hz, J= 7.5 Hz, H-1’), 7.64 (2H, d, J= 8.7 Hz, subs Ph), 7.74 (2H, dd; 
J= 2.1 Hz, J= 8.4 Hz, subs Ph), 7.83 (1H, d, J= 0.9 Hz, H-6). 13C NMR (75 MHz, DMSO-d6): δ 17,11 
(5-CH3), under DMSO (C-2’), 45.62 (C-5’), 70.95 (C-3’), 86.18 and 86.55 (C-4’ and C-1’), 117.22 (C-5), 
124.61, 127.50, 131.77 and 134.28 (CF3 and subs Ph), 139.23 (C-6), 148.00 (C-2), 180.95 (C=S), 
190.70 (C-4). Exact mass (ESI-MS) for C18H19ClF3N4O3S2 [M+H]+ found,495.0508; calcd, 495.0534. 
5’-(4-Chlorophenyl-1,2,3-triazol-1-yl)-5’-deoxy-α-D-thymidine (20). Compound 17 (85 mg, 0.32 
mmol), sodium ascorbate (3 mg, 0.016 mmol) and CuSO4͘͘ ·5H2O (3 mg, 0.013 mmol) were 
suspended in 3 mL of H2O/t-BuOH (2:1). 1-Chloro-4-ethynylbenzene (87 mg, 0.64 mmol) was added 
after 15 minutes and the mixture was stirred at room temperature for 4 days. Water was added and 
the triazole product precipitated. Filtration of the mixture afforded pure compound 20 (40.0 mg, 31%) 
as a white powder. 1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, d, J= 1.2 Hz, 5-CH3), 1.94 (1H, app t, 
J= 3.9 Hz, H-2’a), 1.99 (1H, app t, J= 3.9 Hz, H-2’b), 4.22-4.32 (1H, m, H-4’), 4.43-4.66 (3H, m, H-3’, 
H-5’a and H-5’b), 5.65 (1H, br s, 3’-OH), 6.18 (1H, dd, J= 4.2 Hz, J= 7.5 Hz, H-1’), 7.49-7.54 (2H, m, 
subs Ph), 7.72 (1H, d, J= 1.2 Hz, H-6), 7.86-7.91 (2H, m, subs Ph), 8.62 (1H, s, H-5”), 11.26 (1H, s, 3-
NH). 13C NMR (75 MHz, DMSO-d6): δ 12.15 (5-CH3), 51.20 (C-5’), 70.53 (C-4’), 84.72 (C-1’), 85.37 (C-
3’), 108.81 (C-5), 122.41 (C-5”), 126.73, 128.83, 129.45 and 132.15 (subs Ph), 136.64 (C-6), 145.12 
(C-4”), 150.29 (C-2), 163.65 (C-4). Exact mass (ESI-MS) for C18H19ClN5O4 [M+H]+ found, 404.1129; 
calcd, 404.1120. 
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5’-O-Acetyl-3’-azido-3’-deoxy-α-D-thymidine (38). To a solution of compound 37 (642 mg, 2.08 
mmol) in 1 mL anhydrous CH2Cl2, was added a freshly prepared solution, containing 34 μL H2SO4 and 
140 μL acetic acid anhydride in 1 mL anhydrous CH2Cl2. After 2 h, the mixture was quenched with 
saturated NaHCO3-solution and extracted three times with EtOAc. Purification of the crude on a silica 
gel column (EtOAc/hexane 9:1) yielded compound 38 as a white foam (126 mg, 20%). 1H NMR (300 
MHz, DMSO-d6): δ 1.80 (3H, d, J= 0.9 Hz, 5-CH3), 2.06 (3H, s, OAc), 2.15-2.22 (1H, m, H-2’a), 2.70-
2.75 (1H, m, H-2’b), 4.11-4.14 (2H, m, H-5’a and H-5’b), 4.34-4.39 (1H, m, H-3’), 4.42-4.45 (1H, m, H-
4’), 6.07 (1H, dd, J= 6.0 Hz, J= 6.9 Hz, H-1’), 7.59 (1H, d, J= 1.2 Hz, H-6), 11.32 (1H, s, 3-NH). 13C 
NMR (75 MHz, DMSO-d6): δ 12.15 (5-CH3), 20.62 (OAc), 36.23 (C-2’), 60.43 (C-3), 63.68 (C-5’), 81.46 
(C-4’), 84.93 (C-1’), 109.38 (C-5), 136.25 (C-6), 150.36 (C-2), 163.80 (C-4), 170.15 (OAc). Exact mass 
(ESI-MS) for C12H16N5O5 [M+H]+ found, 310.1164; calcd, 310.1146. Spectroscopic data of 38 were in 
accordance with literature data.23
3’-Azido-3’-deoxy-α-D-thymidine (21). Compound 38 (146 mg, 0.47 mmol) was dissolved in a 7N 
NH3 in MeOH solution (2.6 mL) and stirred at room temperature for 6 hours. The reaction mixture was 
concentrated in vacuo and the residue was purified on a silica gel column using EtOAc/hexane (8:2) 
as the eluent to afford compound 21 as a colorless solid (91 mg, 72%). 1H NMR (300 MHz, CDCl3): δ 
1.95 (3H, d, J= 0.9 Hz, 5-CH3), 2.12-2.17 (1H, m, H-2’a), 2.82-2.91 (1H, m, H-2’b), 3.08 (1H, t, J= 5.4 
Hz, 5’-OH), 3.65-3.72 (1H, m, H-5’a), 3.81-3.85 (1H, m, H-5’b), 4.27-4.35 (2H, m, H-3’ and H-4’), 6.29 
(1H, dd, J= 4.2 Hz, J= 6.9 Hz, H-1’), 7.32 (1H, d, J= 1.5 Hz, H-6), 9.48 (1H, s, 3-NH). 13C NMR (75 
MHz, CDCl3): δ 12.67 (5-CH3), 38.22 (C-2’), 60.83 (C-3), 62.62 (C-5’), 85.93 and 86.02 (C-4’ and C-
1’), 111.24 (C-5), 135.35 (C-6), 150.72 (C-2), 164.03 (C-4). Exact mass (ESI-MS) for C10H14N5O4 
[M+H]+ found, 268.1020; calcd, 268.1040. Spectroscopic data of 39 were in accordance with literature 
data.
 
23 
3’-(4-Chlorophenyl-1,2,3-triazol-1-yl)-3’-deoxy-α-D-thymidine (22). Compound 21 (72 mg, 0.27 
mmol), sodium ascorbate (3 mg, 0.024 mmol) and CuSO4͘͘ ·5H2O (3 mg, 0.011 mmol) were 
suspended in 3 mL of H2O/t-BuOH (1:2). 1-Chloro-4-ethynylbenzene (74 mg, 0.54 mmol) was added 
after 15 minutes and the mixture was stirred at room temperature for 24 h. The reaction mixture was 
extracted with EtOAc and the combined organic phases were dried over anhydrous MgSO4 and 
evaporated to anhydrousness. The crude product was purified column chromatography 
(EtOAc/hexane 8:2) affording 22 (50.8 mg, 47%) as a white powder. 1H NMR (300 MHz, DMSO-d6): δ 
1.75 (3H, s, 5-CH3), 2.71-2.80 (1H, m, H-2’a), 2.98-3.07 (1H, m, H-2’b), 3.54-3.70 (2H, m, H-5’a and 
H-5’b), 4.65-4.70 (1H, m, H-4’), 5.12 (1H, t, J= 5.4 Hz, 5’-OH), 5.29-5.36 (1H, m, H-3’), 6.26 (1H, app t, 
J= 6.6 Hz, H-1’), 7.50-7.54 (2H, m, subs Ph), 7.63 (1H, d, J= 1.2 Hz, H-6), 7.84-7.87 (2H, m, subs Ph), 
8.82 (1H, s, H-5”), 11.29 (1H, s, 3-NH). 13C NMR (75 MHz, DMSO-d6): δ 12.18 (5-CH3), 37.12 (C-2’), 
59.23 (C-3), 61.12 (C-5’), 83.89 (C-4’), 84.43 (C-1’), 109.58 (C-5), 121.38 (C-5”), 126.88-132.47 (subs 
Ph), 136.07 (C-6), 145.49 (C-4”), 150.46 (C-2), 163.78 (C-4). Exact mass (ESI-MS) for C18H19ClN5O4 
[M+H]+ found, 404.1156; calcd, 404.1120. 
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